1801 Stock Overview
A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$35.20 |
| 52 Week High | HK$52.15 |
| 52 Week Low | HK$28.30 |
| Beta | 0.24 |
| 1 Month Change | -8.57% |
| 3 Month Change | -17.37% |
| 1 Year Change | -8.09% |
| 3 Year Change | -28.74% |
| 5 Year Change | n/a |
| Change since IPO | -38.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1801 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.9% | -3.9% | -0.5% |
| 1Y | -8.1% | -5.7% | 19.9% |
Return vs Industry: 1801 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.
Return vs Market: 1801 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 1801 volatility | |
|---|---|
| 1801 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 1801 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1801's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5,263 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23.
Innovent Biologics, Inc. Fundamentals Summary
| 1801 fundamental statistics | |
|---|---|
| Market cap | HK$57.65b |
| Earnings (TTM) | -HK$1.37b |
| Revenue (TTM) | HK$7.95b |
7.3x
P/S Ratio-42.2x
P/E RatioIs 1801 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1801 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.46b |
| Cost of Revenue | CN¥2.12b |
| Gross Profit | CN¥5.34b |
| Other Expenses | CN¥6.62b |
| Earnings | -CN¥1.28b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.78 |
| Gross Margin | 71.58% |
| Net Profit Margin | -17.18% |
| Debt/Equity Ratio | 25.8% |
How did 1801 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 10:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Innovent Biologics, Inc. is covered by 53 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Linda Lu | BOCI Research Ltd. |
| Wai Chak Yuen | BOCI Research Ltd. |
| Bo Li | BofA Global Research |